🇬🇧 Unleashing single-cell technologies for next generation drug development
Nov 22, 2023 — 11:40 am CET - 11:50 AM CET
One Bio is unleashing single-cell sequencing of large retrospective patient cohorts, heavily relying on frozen samples analysis, which has been a major hurdle of the field. This is based on technological breakthroughs in sequencing as well as on data analysis. One Bio is a spin off from Institut Curie, supported by Home Biosciences, a venture builder financed by Sofinnova and Redmile. One Bio is based in Paris and gathers a team of great biologists and data scientists. We are translating this unique technology into new drug development in oncology and other indications. I will support the acceleration of the company and we target an ambitious series A financing next year.